OBJECTIVE: The uptake of 3'-[18F]fluoro-3'-deoxythymidine (FLT), a proliferation marker, was measured before and during fractionated radiotherapy to evaluate the potential of FLT-positron emission tomography (PET) imaging as an indicator of tumor response compared to 2'-deoxy-2'-[18F]fluoro-D-glucose (FDG). MATERIALS AND METHODS: Nude mice bearing established human head and neck xenografts (HNX-OE; nu/nu mice) were locally irradiated (three fractions/week; 22 Gy) using a 150-kVp unit. Multiple FDG- and FLT-PET scans were acquired during treatment. Tumor volume was determined regularly, and tissue was analyzed for biomarkers involved in tracer uptake. RESULTS: Both groups revealed a significant decline in tumor volume (P<0.01) compared to untreated tumors. For FDG as well as for FLT, a significant decline in retention was observed at day 4. For FLT, most significant decline in retention was observed at day 12; whereas, for FDG, this was already noted at day 4. Maximum decline in tumor-to-nontumor ratios (T/NT) for FDG and FLT was 42+/-18% and 49+/-16% (mean+/-SD), respectively. FLT uptake was higher then that of FDG. For FLT, statistical significant correlations were found for both tumor volume at baseline and at day 29 with T/NT and DeltaT/NT. All tumors demonstrated expression of glucose transporter-1, thymidine kinase-1, and hexokinase II. No differences were found for amount of tumor cells and necrosis at the end of treatment. CONCLUSION: This new experimental in vivo model supports the promise of using FLT-PET, as with FDG-PET, to monitor response to external radiotherapy. This warrants further clinical studies to compare these two tracers especially in cancers treated with radiotherapy.
OBJECTIVE: The uptake of 3'-[18F]fluoro-3'-deoxythymidine (FLT), a proliferation marker, was measured before and during fractionated radiotherapy to evaluate the potential of FLT-positron emission tomography (PET) imaging as an indicator of tumor response compared to 2'-deoxy-2'-[18F]fluoro-D-glucose (FDG). MATERIALS AND METHODS:Nude mice bearing established human head and neck xenografts (HNX-OE; nu/nu mice) were locally irradiated (three fractions/week; 22 Gy) using a 150-kVp unit. Multiple FDG- and FLT-PET scans were acquired during treatment. Tumor volume was determined regularly, and tissue was analyzed for biomarkers involved in tracer uptake. RESULTS: Both groups revealed a significant decline in tumor volume (P<0.01) compared to untreated tumors. For FDG as well as for FLT, a significant decline in retention was observed at day 4. For FLT, most significant decline in retention was observed at day 12; whereas, for FDG, this was already noted at day 4. Maximum decline in tumor-to-nontumor ratios (T/NT) for FDG and FLT was 42+/-18% and 49+/-16% (mean+/-SD), respectively. FLT uptake was higher then that of FDG. For FLT, statistical significant correlations were found for both tumor volume at baseline and at day 29 with T/NT and DeltaT/NT. All tumors demonstrated expression of glucose transporter-1, thymidine kinase-1, and hexokinase II. No differences were found for amount of tumor cells and necrosis at the end of treatment. CONCLUSION: This new experimental in vivo model supports the promise of using FLT-PET, as with FDG-PET, to monitor response to external radiotherapy. This warrants further clinical studies to compare these two tracers especially in cancers treated with radiotherapy.
Authors: M J Welters; A M Fichtinger-Schepman; R A Baan; M A Hermsen; W J van der Vijgh; J Cloos; B J Braakhuis Journal: Int J Cancer Date: 1997-05-02 Impact factor: 7.396
Authors: E Brun; T Ohlsson; K Erlandsson; E Kjellén; A Sandell; J Tennvall; J Wennerberg; S E Strand Journal: Acta Oncol Date: 1997 Impact factor: 4.089
Authors: Jason L J Dearling; Aiden A Flynn; Julie Sutcliffe-Goulden; Ingrid A Petrie; Robert Boden; Alan J Green; Geoffrey M Boxer; Richard H J Begent; R Barbara Pedley Journal: J Nucl Med Date: 2004-01 Impact factor: 10.057
Authors: David C P Cobben; Bernard F A M van der Laan; Bram Maas; Willem Vaalburg; Albert J H Suurmeijer; Harald J Hoekstra; Pieter L Jager; Philip H Elsinga Journal: J Nucl Med Date: 2004-02 Impact factor: 10.057
Authors: Henryk Barthel; Meg Perumal; John Latigo; Qimin He; Frank Brady; Sajinder K Luthra; Pat M Price; Eric O Aboagye Journal: Eur J Nucl Med Mol Imaging Date: 2004-09-04 Impact factor: 9.236
Authors: Astrid A M van der Veldt; Lotty Hooft; Paul J van Diest; Johannes Berkhof; Marrije R Buist; Emile F I Comans; Otto S Hoekstra; Carla F M Molthoff Journal: Eur J Nucl Med Mol Imaging Date: 2006-07-14 Impact factor: 10.057
Authors: M H Pan; S C Huang; Y P Liao; D Schaue; C C Wang; D B Stout; J R Barrio; W H McBride Journal: Mol Imaging Biol Date: 2008-08-01 Impact factor: 3.488
Authors: Neale S Mason; Brian J Lopresti; James Ruszkiewicz; Xinxin Dong; Sonali Joyce; George Leef; Malabika Sen; Abdus S Wahed; Chester A Mathis; Jennifer R Grandis; Sufi M Thomas Journal: Am J Nucl Med Mol Imaging Date: 2013-01-05